Relationship between the humoral link of immunity, cytokine regulation with short-chain fatty acids in patients with inflammatory bowel diseases
Keywords:shortchain fatty acids, humoral immunity, cytokines, ulcerative colitis, Crohn’s disease
Background. The pathogenesis of chronic inflammatory bowel disease (IBD) is still not fully clarified. Modern research is aimed at studying the state of humoral immunity, production and intestinal absorption of short-chain fatty acids (SCFA). The purpose was to assess the state of the humoral part of immunity, cytokine regulation and the content of short-chain fatty acids in the feces of patients with IBD. Materials and methods. The study, which was carried out at the Department of Intestinal Diseases of the Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine, involved 34 patients with IBD: group I — those with ulcerative colitis (UC) (n = 25), group II — individuals with Crohn’s disease (n = 9). Determination of fecal SCFA, level of CD22+ lymphocytes, immunoglobulins A, M, G, interleukin-10 and TNF-α was determined. Results. There was a decrease in the humoral level of immunity, increase in the content of propionic (C3) acid (p < 0.001) and a decrease in acetic (C2) (p < 0.001) and butyric (C4) (p < 0.001) acids in the coprofiltrate of patients with IBD. The level of TNF-α was significantly higher in patients with mild UC (13.3 times, p < 0.05), in patients with moderate UC (17.4 times, p < 0.05) and in patients with Severe UC (19.4 times, p < 0.05) compared with its level in the control group; it was found that in the group of patients with severe UC there was a significant decrease in the content of butyric acid (C4) in 2.8 times relative to the control group (p < 0,01). Conclusions. In our study, a relationship was established between the level of humoral immunity, cytokine regulation and the content of FFA in feces, which may indicate the participation of intestinal metabolites in the activation of human immunity.
Dorofeyev, AE, Tkach SM, Dorofeyeva АA, Moseiko VV, Derkach IA, Kiryan EA. Influence of basic therapy on the intestinal microbiota composition in patients with ulcerative colitis. Gastroenterologia. 2020;54(2):10-14. (in Ukrainian).
Carstens А. The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clin. Transl. Gastroenterol. 2019 Jul;10 (7):e00065. doi:10.14309/ctg.0000000000000065.
Stepanov YuM, Skyrda IYu, Petishko OP. Chronic inflammatory bowel diseases: epidemiological features in Ukraine. Gastroenterologia. 2017;51(2):97-105. doi: 10.22141/2308-2097.51.2.2017.101703. (in Ukrainian).
Stepanov YuM, Psareva IV. The role of biomarkers in the diagnostics of chronic inflammatory bowel diseases Gastroenterologia. 2017;51(1):56-63. doi: 10.22141/2308-2097.51.1.2017.97872. (in Ukrainian).
Psareva IV. Association of biomarkers of intestinal inflammation with indexes of ulcerative colitis activity. Gastroenterologia. 2020;54(1):38-43. doi: 10.22141/2308-2097.54.1.2020.199140. (in Ukrainian).
Tsai Y-W , Fu S-H, Dong J-L, Chien M-W, Liu Y-W, Hsu C-Y, Sytwu H-K. Adipokine-Modulated immunological homeostasis shapes the pathophysiology of inflammatory bowel disease. Int J Mol Sci. 2020 Dec15;21(24):9564. doi: 10.3390/ijms21249564.
Dorofeyev AE, Rassokhina OО. Genetic determinism of the intestinal microbiome changes and its role in pathogenesis of inflammatory bowel diseases. Modern gastroenterology. 2013;(6):61-69. (in Russian).
Khan I, Ullah N, Zha L, Bai Y, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019 Sep;8(3):126. doi: 10.3390/pathogens8030126.
Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Mar 11;10:277. doi: 10.3389/fimmu.2019.00277.
Scott NA, Andrusaite A, Andersen P, et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci Transl Med. 2018 Oct 24;10(464):eaao4755. doi: 10.1126/scitranslmed.aao4755.
Skrypnyk IМ, Kryvoruchko IH, Gopko OF, Prykhodko NP. Influence of Bifidobacterium infantis 35624 on the clinical course of irritable bowel syndrome depending on the phenotype: results of a local non-interventional prospective epidemiological study IBS-Control. Modern gastroenterology. 2020;(4):13-21. doi: 10.30978/MG-2020-4-13. (in Ukrainian).
Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017 Apr;32(4):769-777. doi: 10.1111/jgh.13612.
Armstrong H, Alipour M, Valcheva R, et al. Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases. Microbiome. 2019 Jan3;7(1):1. doi: 10.1186/s40168-018-0604-3.
Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4):379-389. doi: 10.1080/00365521.2018.1447597.
Stepanov YuM, Titova MV, Klenina IA, Tatarchuk OM. Age peculiarities of intestinal microbiocenosis disorders in the patients with ulcerative colitis and Crohn’s disease. Gastroenterologia. 2020;54(4):221-227. doi: 10.22141/2308-2097.54.4.2020.216710.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.